It is made available under a CC-BY-NC-ND 4.0 International license .

1	Article Summary Line: A recent, nationwide mass screening program in Peru's prisons using						
2	digital radiography with automated interpretation and molecular testing identified high						
3	tuberculosis prevalence and rates of rifampicin resistance, highlighting the need for active case-						
4	finding as an efficient strategy to identify undiagnosed TB burden in high-risk populations.						
5	Running Title: National Active Case-Finding for TB in Prisons						
6	Keywords: Mycobacterium tuberculosis, tuberculosis, drug resistance, mass screening,						
7	rifampicin, asymptomatic infections						
8							
9	Title: A National Active Case-Finding Program for Tuberculosis in Prisons, Peru, 2024						
10	Authors: Esther Jung*, Valentina A. Alarcón, Wilfredo Santos Solís Tupes, Tatiana Avalos-						
11	Cruz, Marco Tovar, Erika Abregu, Max Z. Yang, Jason R. Andrews <sup>1</sup> , Moises A. Huaman <sup>1</sup>						
12	<sup>1</sup> These senior authors contributed equally to this article.						
13	*Corresponding Author: Esther Jung, Stanford University School of Medicine, 240 Pasteur Dr,						
14	Stanford, CA 94304-1049, Phone: (858)260-8377, Email: esthjung@stanford.edu						
15	Affiliations:						
16	Stanford University School of Medicine, Stanford, California, USA (E. Jung, M.Z. Yang, J.R.						
17	Andrews)						
18	Dirección de Prevención y Control de Tuberculosis (DPCTB), Ministerio de Salud, Lima, Perú						
19	(V.A. Alarcón, W.S. Solís Tupes, T. Avalos-Cruz, E. Abregu)						
20	Instituto de Investigación Nutricional, Lima, Perú (M. Tovar)						
21	University of Cincinnati College of Medicine, Cincinnati, Ohio, USA (M.A. Huaman)						
22							

It is made available under a CC-BY-NC-ND 4.0 International license .

#### 24 Abstract

From January to September 2024, a national active case-finding program in Peru's prisons screened more than 38,000 incarcerated persons for tuberculosis using chest radiography with automated interpretation and rapid molecular diagnostics, yielding a tuberculosis prevalence of 2,800 per 100,000 persons, with 11.4% of cases rifampicin-resistant; 42.5% of cases were subclinical.

30

## 31 **The Study**

Global tuberculosis (TB) incidence has slowly declined over the past decade, but prisons, especially in Latin America, have seen alarming increases in TB incidence over the same period (1). Overcrowding, poor ventilation, and diagnostic delays amplify tuberculosis transmission, such that incidence rates in this region are 27 times higher among persons deprived of liberty (PDL) compared to the general population (2). The rise in tuberculosis in Latin America's prisons has more than offset reductions in TB in the general population, undermining progress towards the *End TB* goals (*3*).

39 To address this disproportionate burden, the World Health Organization (WHO) now 40 recommends active case-finding (ACF) for TB in prisons (4). However, few standardized efforts 41 have been made to implement nationwide screening for TB in prisons in low- and middle-42 income countries (LMICs). There remains a critical need for evidence-based, efficient 43 implementation strategies that are sustainable in real-world settings. The Peruvian National TB 44 Program (DPCTB) recently initiated a country-wide screening strategy using chest radiography 45 (CXR) with computer-detection software, clinical evaluation and molecular rapid diagnostics in 46 high TB-burdened prisons. We sought to evaluate the programmatic yield of this initiative and 47 assess how each screening component contributed to identifying tuberculosis cases.

It is made available under a CC-BY-NC-ND 4.0 International license .

48	Peru has a population of 34 million inhabitants and 96,805 prisoners (5,6). In 2022,						
49	national TB incidence was estimated to be 151 cases per 100,000 person-years (6), while						
50	incidence among PDL has been estimated to be 4,194 cases per 100,000 person-years (7). In						
51	2023, DPCTB implemented an active case finding program in 12 male, 1 co-ed, and 5 female						
52	prisons chosen for size, TB burden, and convenience (Figure 1).						
53	Programmatic data from PDL $\geq$ 18 years old who were not being treated for active TB						
54	and received a CXR screening between January and September 2024 were included in this						
55	analysis. The screening team consisted of a physician, nurse, and radiology technician; three						
56	largest prisons included additional lab personnel. Each participant was interviewed to collect						
57	demographic, clinical, and TB-symptom information. All participants were screened with a						
58	portable digital CXR machine, and CXR were evaluated with Computer-Aided Detection for						
59	Tuberculosis (CAD4TB) software version 7.0. CAD4TB assigns a score between 1 and 100						
60	based on radiological abnormalities suggestive of a TB diagnosis. All participants then						
61	underwent clinical evaluation by a physician.						
62	Participants with a CAD4TB score $\geq \Box 40$ (considered "abnormal") were asked to produce						
63	a sputum sample. Participants with a CAD4TB score < 40 (considered "normal") were only						
64	asked to produce a sputum sample if the physician suspected TB based on symptoms and/or						
65	evaluation. A molecular rapid diagnostic test, Xpert MTB/RIF Ultra assay (Cepheid, Sunnyvale;						
66	hereinafter Xpert), was performed on all but 308 sputum samples, which were excluded from						
67	analysis. We defined a TB case as any positive or trace sputum Xpert result. All individuals with						
68	confirmed TB were provided free treatment.						
69	Between January and September of 2024, DPCTB screened 38,734 participants meeting						
70	inclusion criteria: 7,291 (18.8%) had sputum collected, and 6,873 (94.3%) of samples produced						

It is made available under a CC-BY-NC-ND 4.0 International license .

71	valid Xpert results (Figure 2). To evaluate the association between demographic and clinical
72	characteristics and TB, we used multivariable logistic regression with fixed effects for prison to
73	estimate crude (OR) and adjusted (AOR) odds ratios with their respective 95% confidence
74	intervals. We calculated the sputum positivity and proportion of TB cases detected by
75	combinations of symptom screen and CAD4TB results (Table 2). R (version 4.4.1) was used for
76	statistical analyses.
77	Most study participants were male (96%), born in Peru (94%), and median age was 35
78	years old (IQR 27-43). Previous TB history was reported among 16% of participants, and 40%
79	reported prior contact with TB (Table 1).
80	Among all participants, 1,089 (2.8%) were diagnosed with TB. Prevalence ranged from
81	0% in several small prisons (<250 PDL) to 5.6% among 2,053 PDL in Huacho. All five female
82	prisons had a prevalence under 1.5%, while 8 of the 12 male prisons had TB prevalence over 2%.
83	11.4% (124/1089) of Xpert-positive samples tested positive for rifampicin resistance (RR-TB),
84	with four prisons recording RR-TB prevalence among cases of over 10% (Figure 1).
85	5,908 (15.3%) participants had abnormal CAD4TB scores, and 4,613 (11.9%) reported
86	symptoms in the preceding two weeks. Xpert positivity varied substantially according to
87	symptoms and x-ray abnormality. Among individuals with symptoms but normal scores, 6.8%
88	had positive Xpert, representing 7.8% of TB cases detected. Among individuals with abnormal
89	scores but no symptoms, 12.2% had positive Xpert, representing 40.9% of TB cases. Xpert was
90	positive in 26.2% of those with symptoms and abnormal scores, who comprised 49.8% of TB
91	cases (Table 2).
92	Odds of TB were higher among participants with a reported history of TB (AOR: 2.79,

93 95% CI, 2.44-3.19) and contact with TB (AOR: 1.90, 95% CI: 1.55-2.31) (Table 1). Odds of RR-

medRxiv preprint doi: https://doi.org/10.1101/2024.11.08.24317002; this version posted November 11, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

TB were higher among cases with a reported history of TB (AOR: 1.95, 95% CI, 1.32-2.91)
(Supplementary Table 1).

96 Conclusion

97 There is a critical need for successful, scalable models for ACF in LMIC prisons, where 98 estimates suggest that nearly half of cases go undetected annually (7). In Peru, a mass screening 99 strategy led by mobile health teams using CXR with automated interpretation screened over 100 38,000 PDL in eight months, more than one-third of the national incarcerated population, making 101 it one of the largest scale implementations of ACF based in molecular testing in LMIC prisons 102 reported to date. The prevalence of undiagnosed TB was 2,800 per 100,000, with 11.4% of RR-103 TB. More than 40% of individuals with Xpert-confirmed TB lacked symptoms. These findings 104 illustrate the importance of systematic screening in prisons, including among individuals without 105 TB symptoms.

106 This study also presents the first nationally representative prevalence estimates of TB 107 burden in Peru's carceral system based in molecular testing. Since 2020, Peru has remained on 108 the WHO's list of the 30 countries with the highest levels of drug-resistant TB, and it is 109 estimated that 8.3% of new TB diagnoses every year are drug-resistant (6,8). Our study detected 110 a high prevalence of TB (2,800 per 100,000), and a very high proportion (11.4%) of RR-TB. The 111 prevalence estimate was almost certainly an underestimate for these prisons, as sputum was only 112 collected from participants with x-ray abnormalities, symptoms, or clinical suspicion of TB. 113 Including clinical inference as a criterion would likely capture additional TB. However, this 114 study was limited to 18 prisons selected for high TB-burden and convenience, hindering 115 generalizability to other prisons in Peru.

It is made available under a CC-BY-NC-ND 4.0 International license .

116	A hidden threat in high-transmission settings like prisons in LMICs is subclinical TB.							
117	Previous estimates have shown that asymptomatic TB accounts for a considerable proportion of							
118	active disease and overall transmission in both the general and incarcerated population (9-12).							
119	We found 42.5% of all TB cases in this study to be subclinical, likely an underestimate due to the							
120	inclusion of symptoms in the screening algorithm criteria, suggesting that symptom-only case-							
121	finding strategies would delay detection or miss a significant fraction of active TB among PDL.							
122	Our data demonstrate that active case-finding can identify a large reservoir of							
123	undiagnosed tuberculosis and can be performed efficiently at scale in prisons using mobile							
124	radiography with automated interpretation led by teams of health professionals. Such strategies							
125	require incorporation into national TB programs with sustainable financing to roll out and							
126	maintain their implementation at scale in LMIC prisons, where the burden of TB demands urgent							
127	attention.							
128	Acknowledgements							
129	We thank the Peruvian National TB Program team for providing data and assistance during this							
130	study.							
131	Disclosures							
132	The authors present no conflicts of interest. This study was reviewed by the Stanford							
133	Institutional Review Board and was determined not to be human subjects research. This project							
134	has been registered in the INS-Peru study registry (PRISA) (EI00000003259).							
135	Biographical Sketch							
136	Ms. Jung is a research program coordinator at Stanford University School of Medicine. Her							
137	research interests include environmental and infectious disease epidemiology in marginalized							
138	populations.							

It is made available under a CC-BY-NC-ND 4.0 International license .

# 139 **References**

140	1.	Walter KS, Martinez L, Arakaki-Sanchez D, Sequera VG, Sanabria GE, Cohen T, Ko AI,
141		García-Basteiro AL, Rueda ZV, López-Olarte RA, Espinal MA, Croda J, Andrews JR.
142		The escalating tuberculosis crisis in central and South American prisons. The Lancet.
143		2021;397(10284),1591–1596. <u>DOI</u>
144	2.	Cords O, Martinez L, Warren JL, O'Marr JM, Walter KS, Cohen T, Zheng J, Ko AI,
145		Croda J, Andrews JR. Incidence and prevalence of tuberculosis in incarcerated
146		populations: A systematic review and meta-analysis. The Lancet Public Health. 2021;6(5).
147		DOI
148	3.	World Health Organization. The End TB Strategy: Global strategy and targets for
149		tuberculosis prevention, care and control after 2015. 2014 [cited 2024 Aug 23].
150		https://www.who.int/publications/i/item/WHO-HTM-TB-2015.19
151	4.	World Health Organization. Consolidated guidelines on tuberculosis: Module 2:
152		screening – systematic screening for tuberculosis disease. 2021 [cited 2024 Aug 2].
153		http://www.ncbi.nlm.nih.gov/books/NBK569338/
154	5.	World Prison Brief. Peru. 2024 Apr 30 [cited 2024 Jul 13].
155		https://www.prisonstudies.org/country/peru
156	6.	World Health Organization. TB profile. 2022 [cited 2024 Aug 13].
157		https://worldhealthorg.shinyapps.io/tb_profiles/?_inputs_&entity_type=%22country%22
158		<u>&amp;iso2=%22PE%22&amp;lan=%22EN%22</u>
159	7.	Martinez L, Warren JL, Harries AD, Croda J, Espinal MA, Olarte RAL, Avedillo P,
160		Lienhardt C, Bhatia V, Liu Q, Chakaya J, Denholm JT, Lin, Y, Kawatsu L, Zhu L,
161		Horsburgh CR, Cohen T, Andrews, JR. Global, regional, and national estimates of

It is made available under a CC-BY-NC-ND 4.0 International license .

162		tuberculosis incidence and case detection among incarcerated individuals from 2000 to
163		2019: A systematic analysis. The Lancet Public Health. 2023;8(7), e511–e519. DOI
164	8.	World Health Organization. Global Tuberculosis Report 2023. 2023 Nov 7 [cited 2024
165		Jul 23]. https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-
166		tuberculosis-report-2023
167	9.	Frascella B, Richards AS, Sossen B, Emery JC, Odone A, Law I, Onozaki I, Esmail H,
168		Houben, RMGJ. Subclinical Tuberculosis Disease — A Review and Analysis of
169		Prevalence Surveys to Inform Definitions, Burden, Associations, and Screening
170		Methodology. Clinical Infectious Diseases. 2020;73(3), e830–e841. DOI
171	10.	Kendall EA, Shrestha S, Dowdy DW. The Epidemiological Importance of Subclinical
172		Tuberculosis. A Critical Reappraisal. Am J Respir Crit Care Med. 2021 Jan
173		15;203(2):168-174. <u>DOI</u> .
174	11	Puma, D., Yuen, C. M., Millones, A. K., Brooks, M. B., Jimenez, J., Calderon, R. I.,
175		Lecca, L., Becerra, M. C., & Keshavjee, S. (2023). Sensitivity of Various Case Detection
176		Algorithms for Community-based Tuberculosis Screening. Clinical Infectious Diseases,
177		76(3), e987–e989. <u>DOI</u>
178	12.	Puma, D., Geadas, C., Calderon, R. I., Yuen, C. M., Jiménez, J., Córdova, M., Martínez,
179		B., Peinado, J., Lecca, L., & Tovar, M. (2023). Active case-finding for TB among
180		incarcerated women in Peru. The International Journal of Tuberculosis and Lung Disease,
181		27(10), 784. <u>DOI</u>

It is made available under a CC-BY-NC-ND 4.0 International license .

## 183 **Table 1.** Multivariable logistic regression analysis of demographic characteristics and risk

Risk factor	n	TB Confirmed (%)	OR (95% CI)	P value	AOR (95% CI)	P value
Age						
18-29	11193	382 (3.4)				
30-44	17557	486 (2.8)	0.75 (0.65, 0.87)	<.001	0.68 (0.59, 0.78)	<.001
45-60	7708	169 (2.2)	0.58 (0.48, 0.70)	<.001	0.54 (0.45, 0.65)	<.001
$\geq 60$	2274	52 (2.3)	0.61 (0.45, 0.81)	<.001	0.58 (0.42, 0.77)	<.001
Sex						
Male	37227	1081 (2.9)	5.01 (1.60, 30.3)	.024	3.78 (1.20, 22.94)	.062
Female	1507	8 (0.5)				
TB History						
Yes	6232	397 (6.4)	2.85 (2.50, 3.24)	<.001	2.75 (2.41, 3.13)	<.001
No	32502	692 (2.1)				
TB Contact	15459	556 (3.6)	2.15 (1.77, 2.59)	<.001	1.90 (1.56, 2.30)	<.001
Peru Origin	36596	1054 (2.9)	1.80 (1.30, 2.58)	.001	1.67 (1.20, 2.41)	.004

184 factors for tuberculosis among screened PDL.

185 Data are presented as no. (%) unless otherwise indicated. CI, confidence interval; PDL, persons deprived of liberty;

186 TB, tuberculosis; OR, odds ratio; AOR, adjusted odds ratio; PDL, persons deprived of liberty.

It is made available under a CC-BY-NC-ND 4.0 International license .

## **Table 2.** Predictive value of Computer-Aided Detection for Tuberculosis Score, symptom

#### 188 screen, and sputum collection among screened PDL.

CAD4TB	Symptoms	n (%)	Sputum	TB Confirmed	% of TB Cases*	Sputum Positivity %
Score			Collected		(95% CI)	(95% CI)
< 40	Absent	30335 (78.3)	333	17	1.6 (0.9, 2.5)	5.1 (3.0, 8.1)
	Present	2491 (6.4)	1250	85	7.8 (6.3, 9.6)	6.8 (5.5, 8.3)
$\geq 40$	Absent	3786 (9.8)	3642	445	40.9 (37.9, 43.9)	12.2 (11.2, 13.3)
	Present	2122 (5.5)	2066	542	49.8 (46.8, 52.8)	26.2 (24.4, 28.2)
Total		38734	7291	1089		

189 \*TB case defined as any positive or trace Xpert result. CAD4TB, Computer-Aided Detection for Tuberculosis; CI,

190 confidence interval; TB, tuberculosis; PDL, persons deprived of liberty.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 197 **Figure 1.**
- 198 Figure Legend:
- 199 Panel A Map of 18 prisons included in screening procedures, insets magnify Lima/Callao and
- 200 Piura districts.
- 201 Panel B Bar diagram displaying tuberculosis prevalence and rifampicin-resistance (RR-TB) by
- 202 prison, sorted by descending TB prevalence. Dotted line shows overall TB prevalence across all
- 203 prisons (2.8%).
- 204 \*TB case defined as any positive or trace Xpert result. EP, Establecimiento Penitenciario
- 205 (Penitentiary Establishment); Juvenil Miguel Grau, Centro Juvenil de Diagnóstico y
- 206 Rehabilitación Miguel Grau; Mujeres, women's prison, RR-TB, rifampicin-resistant TB; TB,
- 207 tuberculosis, Varones, men's prison.
- 208
- 209 **Figure 2.**
- 210 Figure Legend:
- 211 Flowchart for tuberculosis screening algorithm across 18 study prisons among included
- 212 participants.
- 213 \*TB case defined as any positive or trace Xpert result. CAD4TB, Computer-Aided Detection for
- 214 Tuberculosis; MTB, Mycobacterium tuberculosis; PDL, persons deprived of liberty; TB,
- tuberculosis.
- 216
- 217
- 218
- 219
- 220
- 221



